Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Permitted use of Pharma in Focus

Pharma in Focus includes both free and protected content. Free content is available to all users. Protected content is only available to registered users.

Permitted Use of Pharma in Focus protected content

  1. Pharma in Focus protected content is for the personal use of registered users only. Registered users are those who have paid a subscription for access to protected content. Protected content is any content not made available free of charge on the Pharma in Focus site or via the Pharma in Focus News Alert email.

  2. Registered users may:

    a) Access Pharma in Focus material either from their workplace computer or at home or at a remote computer if away temporarily.

    b) Make one hard copy for personal use

    c) Use the 'email a friend' facility in keeping with condition 3(a) below

  1. Registered users may not:

    a) use the 'email a friend' facility to redistribute Pharma in Focus as a whole or in any quantity or frequency which amounts to any person having substantially the benefit of unrestricted access to Pharma in Focus without having paid a subscription or having a subscription paid on their behalf

    b) use their registered email address, or permit it to be used, to allow others gain access to Pharma in Focus

    c) redistribute Pharma in Focus material to anyone by any other means.

TOP | BACK

Perspective
Whither the GBMA in a biosim dominated market?
The departure of Belinda Wood from the helm of the GBMA presents an opportunity to consider what role this group can play in the future Australian medicines market.
Approvals Action
New heart pain drug registered
Menarini has registered a new heart pain drug while Sanofi continues to add to Clexane options to address its impending patent expiry.
Pipeline Monitor
Gilead scores first win from Kite buyout
Gilead has received its first FDA approval for newly acquired CAR-T Yescarta following its USD12 billion buyout of original sponsor Kite Pharma in August.